Imanivec

Imatinib, the active ingredient in Imanivec, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imanivec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imanivec (imatinib) is a tyrosine kinase inhibitor used in malignancies driven by specific kinase mutations.

- Chronic myeloid leukemia: reduces disease burden and improves survival by targeting BCR‑ABL‑positive cells. - Philadelphia‑positive acute lymphoblastic leukemia: induces remission by inhibiting BCR‑ABL signaling. - Gastrointestinal stromal tumor: controls tumor growth by blocking c‑KIT and PDGFR activity.

Imanivec may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Edema: swelling of the hands, feet, or face. - Fatigue: persistent tiredness. - Muscle cramps: painful tightening of muscles. - Diarrhoea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Neutropenia: dangerously low white‑blood‑cell count. - Thrombocytopenia: reduced platelet levels leading to bleeding risk. - Hepatotoxicity: liver enzyme elevation or injury. - Cardiac failure: signs of reduced heart function. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Pulmonary hypertension: elevated pressure in lung arteries.

Before initiating therapy, clinicians should assess baseline health status and monitor for potential complications.

- Monitor blood counts: perform regular CBC to detect cytopenias. - Assess liver function: check hepatic enzymes periodically. - Evaluate cardiac status: consider ECG or echocardiogram in patients with heart disease. - Review concomitant medications: avoid drugs that strongly affect CYP3A4 metabolism. - Pregnancy and lactation: discuss risks with women of childbearing potential. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Imanivec interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels. - Strong CYP3A4 inducers (e.g., rifampin, phenytoin): may reduce efficacy. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Oral contraceptives: possible reduced hormonal efficacy. - H2‑blockers or antacids: may affect absorption, separate dosing times. - CYP2C8 inhibitors (e.g., gemfibrozil): modest increase in exposure. - Proton‑pump inhibitors: monitor for altered gastric pH affecting drug uptake.